REGN4018 (Ubamatamab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for REGN4018 (Ubamatamab), covering 2025-12-03 to 2025-12-03. Get the full timeline:
Most recent: Clinical Trial Update: Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers [Phase 1, Phase 2]